NCT00207103 is a Phase 1 clinical trial of Brivanib in Tumors, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT00207103?

NCT00207103 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT00207103?

Interventions in NCT00207103: Brivanib, Brivanib, Brivanib, Brivanib, Brivanib, Brivanab.

What condition does NCT00207103 study?

NCT00207103 studies Tumors, Neoplasm Metastasis.

Is NCT00207103 still recruiting?

NCT00207103 is currently completed. Last updated 3 November 2008.

Last reviewed 2008-11-03 · How we verify

NCT00207103

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Completed Phase 1 Last updated 3 November 2008

What this trial tests

Phase 1 trial testing Brivanib in Tumors in 68 participants. Completed in 1 September 2008.

Timeline

1 September 2004

Primary endpoint
1 October 2007

1 September 2008

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	1 September 2004
Primary completion	1 October 2007
Estimated completion	1 September 2008
Sites	8 locations across United States, Canada, Italy, United Kingdom

Drugs / interventions tested

Brivanib — full drug profile →
Brivanib — full drug profile →
Brivanib — full drug profile →
Brivanib — full drug profile →
Brivanib — full drug profile →
Brivanab — full drug profile →

Conditions studied

Tumors — all drugs for Tumors →
Neoplasm Metastasis — all drugs for Neoplasm Metastasis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Tumors or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety assessment
Time frame: throughout the study
dose-limiting toxicity (DLT)
Time frame: assessed for individual patients from C1D1 to C1D28 during the dose escalation portion of the protocol, until maximum tolerated dose is identified
determination of maximum tolerated dose (MTD)
Time frame: during dose escalation portion of the protocol. Three to six subjects are treated at a specified dose level. If deemed safe dose escalation continues until the maximum tolerated dose is identified

Sponsor's own description

This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Brivanib

Trials testing the same drug.

NCT00908752 — Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC · Phase 3 · completed
NCT00825955 — Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Fai · Phase 3 · completed

Other recruiting trials for Tumors

Currently open trials in the same condition.

NCT05697406 — HP Pyruvate MRI in Cancers · Phase 1, PHASE2 · recruiting
NCT05103358 — Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 G · Phase 2 · active not recruiting
NCT05103969 — Cohort of Tumors With POLE/D1 Mutation · recruiting
NCT04950959 — XACT ACE Observational Registry · recruiting
NCT04341181 — ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · Phase 2 · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00207103 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 3 November 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00207103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing